NCT07102394 2026-02-17
Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1
Johns Hopkins University
Phase 1 Recruiting
Clinical Trials
20 trialsNCT05957679 2026-02-12
MRE Evaluation for Spinal Cord Tumor Surgery: Stiffness and Adhesion Assessment
Shengjing Hospital
Phase NA Recruiting
NCT06322342 2025-12-26
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
Reveal Pharmaceuticals Inc.
Phase 2 Completed
NCT06300502 2025-11-20
Assessing the Efficacy of Repeat, Monthly Treatments of Deoxycholate for NF1 Associated Cutaneous Neurofibromas (cNFs)
Massachusetts General Hospital
Phase 1 Enrolling by invitation
NCT03962543 2025-08-07
ReNeu
SpringWorks Therapeutics, Inc.
Phase 2 Active not recruiting
NCT02728388 2025-05-08
Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II
Medical College of Wisconsin
Phase 2 Recruiting
NCT03231306 2025-05-02
NF108-BINI
University of Alabama at Birmingham
Phase 2 Completed
NCT05199376 2024-02-09
CryoNF1
Centre Leon Berard
Phase NA Recruiting
NCT02332902 2023-12-20
DCLNF1
The University of Texas Health Science Center, Houston
Phase 2 Completed
NCT00846430 2023-08-30
Medical Treatment of "High-Risk" Neurofibromas
Corewell Health West
Phase 2 Completed
NCT03820778 2021-03-02
Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1
Children's National Research Institute
Phase NA Active not recruiting
NCT01347307 2020-06-18
Stereotactic Body Radiotherapy for Spine Tumors
Mercy Research
Phase NA Completed
NCT02096471 2019-01-10
MEK Inhibitor
University of Alabama at Birmingham
Phase 2 Completed
NCT00021541 2018-04-17
R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02988726 2017-07-26
Antineoplaston Therapy in Treating Patients With Neurofibroma and Schwannoma
Burzynski Research Institute
Phase 2 Terminated
NCT01275586 2017-04-12
Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
Indiana University
Phase EARLY_PHASE1 Completed
NCT01567787 2017-02-10
NF01
University of Florida
Phase NA Withdrawn
NCT00657202 2016-07-07
Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1
Massachusetts General Hospital
Phase EARLY_PHASE1 Completed
NCT00716469 2015-04-15
PDT
Children's Hospital of Philadelphia
Phase 1 Terminated
NCT01031901 2012-02-27
Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)
The University of Texas Health Science Center, Houston
Phase 1 Completed